Press releases
-
Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024
-A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 with notable differences observed as early as Week 4 No treatment-related serious adverse events occurred with SI-6603 Additional analysis presented at ASPN evaluated economic burden of lumbar disc herniation surgery Parsippany, NJ – July 15, 2024 – Ferring Pharmaceuticals and its clinical […]
-
Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
-Parsippany, NJ – June 24, 2024 – Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of two analyses of data at the American Society of Pain and Neuroscience (ASPN) 2024 Annual Meeting, for SI-6603, an investigational therapy intended to treat radicular leg pain associated with lumbar disc herniation (LDH). The congress will take place […]
-
Ferring Pharmaceuticals and Posterity Health Launch New Partnership to Activate Men About Their Fertility
-1 in 6 people worldwide experience infertility and up to 50% of the time there is a contributing male factor.1,2,3 Stigma, lack of awareness and longer-lead times for the initial male fertility evaluation may impact a couple’s path to parenthood. […]